Corrigendum to "Glutathione Peroxidase Level in Patients with Vitiligo: A Meta-Analysis".

[This corrects the article DOI: 10.1155/2016/3029810.].

Fractional CO2 lasers contribute to the treatment of stable non-segmental vitiligo.

BACKGROUND: Stable non-segmental vitiligo is often resistant to conventional therapies. OBJECTIVES: The purpose of this study was to investigate the effect of three types of fractional lasers in the treatment of stable non-segmental vitiligo. MATERIALS & METHODS: Twenty patients were enrolled in the study. The vitiligo lesions of each patient were divided into four treatment parts, and all parts were treated with narrowband ultraviolet-B (NB-UVB). Three of the four parts were respectively treated with three types of fractional lasers (two ablative 10,600-nm CO2 lasers and one non-ablative 1,565-nm laser), followed by topical betamethasone solution application. The treatment period lasted six months. Efficacy and satisfaction were respectively assessed by dermatologists and patients. RESULTS: The ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, achieved marked to excellent improvement on white patches assessed by dermatologists. Patients showed high satisfaction scores for the treatments. The non-ablative 1,565-nm fractional laser did not provide any further benefit in the treatment of vitiligo. No severe adverse events developed for any of the treatments. CONCLUSION: The treatment protocol with ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, was suitable for stable non-segmental vitiligo. For vitiligo, the ablative fractional CO2 laser is more effective than the non-ablative fractional laser.

The Prevalence of Vitiligo: A Meta-Analysis.

OBJECTIVE: To conduct a meta-analysis assessing the prevalence of vitiligo. METHODS: Literatures that reported prevalence rates of vitiligo were identified using EMBASE, PubMed, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang database and Weipu database for the period from inception to May 2016. We performed stratified analyses on possible sources of bias, including areas difference, years of publication, gender and age. Publication bias was assessed with Egger's test method. RESULTS: A total of 103 studies were eligible for inclusion. The pooled prevalence of vitiligo from 82 population- or community-based studies was 0.2% (95%CI: 0.1%-0.2%) and from 22 hospital-based studies was 1.8% (95%CI: 1.4%-2.1%). A relatively high prevalence of vitiligo was found in Africa area and in female patients. For population- or community-based studies, the prevalence has maintained at a low level in recent 20 years and it has increased with age gradually. For hospital-based studies, the prevalence has showed a decreased trend from 60s till now or from young to old. No significant publication bias existed in hospital-based studies (t = 0.47, P = 0.643), while a significant publication bias existed in population- or community-based studies (t = 2.31, P = 0.026). CONCLUSION: A relatively high prevalence of vitiligo was found in Africa area and in female patients. The prevalence has maintained at a low level in recent years. It showed an inverse trend with age increment in population- or community-based studies and hospital-based studies.

Glutathione Peroxidase Level in Patients with Vitiligo: A Meta-Analysis.

Abnormality of glutathione peroxidase (GPx) is involved in the etiology and pathogenesis of vitiligo. However, the results were controversial. Aim. The purpose of this meta-analysis is to compare the levels of GPx between vitiligo patients and healthy controls. Methods. Relevant published articles were searched according to eligibility criteria. A meta-analysis was conducted to pool estimates of the standardized mean difference (SMD) with 95% confidence interval (CI). Results. Twenty-three studies with a total of 1076 vitiligo patients and 770 healthy controls were included. The pooled meta-analysis showed that patients with vitiligo had equivalent levels of GPx with the healthy controls (SMD = -0.47, 95% CI: -1.03 to 0.08, and p = 0.095). Further subgroup analysis showed that the GPx levels of Asian patients or segmental vitiligo patients were, respectively, lower than those of healthy controls (Asian: SMD = -0.47, 95% CI: -1.08 to 0.14, and p = 0.001; segmental: SMD = -3.59, 95% CI: -6.38 to -0.80, and p = 0.012). Furthermore, the GPx levels in serum/plasma were significantly decreased in either stable or active vitiligo patients, comparing to healthy controls (stable: SMD = -2.01, 95% CI: -3.52 to -0.49, and p = 0.009; active: SMD = -2.34, 95% CI: -4.07 to -0.61, and p = 0.008). Conclusion. This meta-analysis showed a significant association between low GPx level and vitiligo.